Clinical trials: Patients With Diabetes.
Diabetic Foot Ulcer, Pressure Injury
A Dual-center Study Evaluating Clinical Acceptance of a NPWT Wound Care System
The purpose of this study is to determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.
- Conditions
- Diabetic Foot Ulcer, Pressure Injury, Pressure Ulcer, Surgical Wound
- Trial name
- NCT04593693
- Testing
- Invia Motion Endure NPWT system
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Medela AG
Diabetes
A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of saxagliptin administered before breakfast for 14 consecutive days in patients with type 2 diabetes mellitus.
- Trial name
- NCT01162876
- Testing
- saxaglipitin
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Type 2 Diabetes
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes.
- Trial name
- NCT00263276
- Testing
- dapagliflozin, metformin
- Where
- 144 sites in United States, Canada and 2 more
- Volunteers
- 389 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus
This study will compare LY900014, a drug that lowers blood sugar, with insulin lispro (Humalog). Both drugs will be given by injection under the skin of the abdomen.
- Trial name
- NCT03407118
- Testing
- LY900014, Insulin Lispro
- Where
- Japan
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)
The present study aims to evaluate the efficacy and safety of different combinations of oral antidiabetics in patients with inadequate glycemic control on metformin monotherapy.
- Trial name
- TRIAD (NCT06560333)
- Testing
- N0892
- Where
- Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study of Multiple Doses of LY2922470 in Participants With Diabetes
The main purpose of this study is to determine the safety of LY2922470, taken as oral capsules, once or twice daily for approximately 28 days, in participants with diabetes.
- Trial name
- NCT01867216
- Testing
- LY2922470
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
Hypoglycemia
Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to moderate hypoglycemia, a complication of…
- Trial name
- NCT02081014
- Testing
- G-Pen Mini™ (glucagon injection)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Xeris Pharmaceuticals
Type 2 Diabetes, Chronic Obstructive Pulmonary Disease
Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease
This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar…
- Trial name
- NCT05492448
- Testing
- L. salivarius AP-32 and L. reuteri GL-104, L. reuteri GL-104
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Glac Biotech Co., Ltd
Diabetes Mellitus
Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.
The purpose of this study is to determine the efficacy of pioglitazone compared to glibenclamide, once daily (QD), taken together with metformin and lifestyle modification in type 2 diabetic subjects with cardiovascular disease.
- Trial name
- SPLENDOR (NCT00770835)
- Testing
- Pioglitazone and Metformin, Glibenclamide and Metformin
- Where
- 2 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug…
- Trial name
- NCT00106340
- Testing
- vildagliptin, glimepiride, Metformin
- Where
- 2 sites in United States, Germany
- Volunteers
- 3,118 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus Type 2
A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes
This randomized, double-blind, placebo-controlled, cross-over study will evaluate the glucose concentration and other glycemic parameters of efficacy, and the safety and tolerability and pharmacokinetics of single oral doses of…
- Trial name
- NCT01044017
- Testing
- RO4998452
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus Type 2
A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus
This randomized, double-blind, placebo-controlled study will assess the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of RO5095932 in patients with type 2 diabetes mellitus.
- Trial name
- NCT00961909
- Testing
- RO5095932, metformin
- Where
- 6 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Insulin Glargine During and After the Period of Fasting in Ramadan
Primary Objectives : To compare the number of hypoglycaemic events (severe, symptomatic, asymptomatic, nocturnal) in patients with type 2 diabetes treated with insulin glargine (Lantus®) and glimepiride (Amaryl®), before, during…
- Trial name
- NCT00258804
- Testing
- Insulin glargine
- Volunteers
- 450 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to…
- Trial name
- IOOX (NCT00377858)
- Testing
- Insulin lispro mid mixture (MM), Insulin glargine
- Where
- 25 sites in Australia, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Hypertension
Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
The study will assess the efficacy and tolerability of MK0736 in patients with Type 2 Diabetes Mellitus and Hypertension who are on ongoing therapy with Angiotensin-Converting Enzyme or Angiotensin Receptor Blocker.
- Trial name
- NCT00806585
- Testing
- MK-0736, Comparator: HCTZ
- Volunteers
- 620 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1…
- Trial name
- NCT03993132
- Testing
- Empagliflozin, Liraglutide
- Where
- Denmark
- Volunteers
- 26,774 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Evaluation of the Blood Levels of the Drug (Lixisenatide), the Plasma Glucose Levels and Safety in Paediatric and Adult Patients With Type 2 Diabetes
Primary Objective: To investigate the effects of two single subcutaneous lixisenatide doses (5 and 10 µg) as compared to placebo in reducing postprandial glucose (PPG) in type 2 diabetic paediatric population (10-17 years old)…
- Trial name
- NCT01572649
- Testing
- Lixisenatide (AVE0010)
- Where
- 6 sites in United States, Mexico and 2 more
- Volunteers
- 24 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.